# How Darolutamide Plus Hormone Therapy Works for Men With Advanced Prostate Cancer in Everyday Medical Practice in Germany

> **NCT07395804** · — · NOT_YET_RECRUITING · sponsor: **Bayer** · enrollment: 500 (estimated)

## Conditions studied

- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

## Interventions

- **DRUG:** Darolutamide plus ADT treatment

## Key facts

- **NCT ID:** NCT07395804
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-28
- **Primary completion:** 2031-02-28
- **Final completion:** 2031-02-28
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07395804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07395804, "How Darolutamide Plus Hormone Therapy Works for Men With Advanced Prostate Cancer in Everyday Medical Practice in Germany". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07395804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*